Nuclear factor-kB (NF-kB) is usually maintained in an inactive form in the cytoplasm through its association with inhibitor of kappaB (IkB) proteins, and is activated upon stimulation of cells with a variety of signals. However, constitutive activation of NF-kB is observed in a number of cancers including breast cancer. The signaling pathways that are involved in constitutive NFkB activation remain largely unknown. Using breast cancer cell lines derived from transgenic mice that overexpress speci®c oncogene/growth factors in the mammary gland, we show that heregulin but not her2/ neu, c-Myc or v-Ha-ras plays a major role in constitutive NF-kB activation. Her2/neu potentiated tumor necrosis factor alpha (TNFa)-inducible NF-kB activation whereas c-Myc potentiated 12-o-tetracecanyolphorbol-13-acetate (TPA)-induced NF-kB activation. Heregulin-mediated NF-kB activation correlated with phosphorylation of epidermal growth factor receptor (EGFR) and ErbB3 but not her2/neu. Tryphostin AG1517, which inhibits heregulin-mediated phosphorylation of EGFR, her2/neu and ErbB3 reduced NF-kB activation. In contrast, emodin, which blocks phosphorylation of her2/neu by heregulin, failed to reduce NF-kB activation. These results suggest that heregulin induces NF-kB independent of her2/neu. PI3 kinase/AKT, protein kinase A (PKA) and IkB kinase appear to be downstream signaling molecules involved in NF-kB activation as speci®c inhibitors of these kinases but not inhibitors of ERK/MAP kinase or protein kinase C reduced heregulin-mediated NF-kB activation. Based on these results, we propose that heregulin increases the expression of pro-invasive, prometastatic and anti-apoptotic genes in cancer cells through autocrine activation of NF-kB, which leads to invasive and drug-resistant growth of breast cancer.
Introduction
The transcription factor NF-kB plays a major role in in¯ammation, cell survival, transformation and oncogenesis Ghosh et al., 1998; Rayet and Gelinas, 1999) . NF-kB is a heterodimeric complex of Rel family proteins which is physically con®ned to the cytoplasm of normal cells through its interaction with inhibitor of kappaB (IkB) proteins . A heterodimer composed of p50 and p65 subunits is the predominant form of NF-kB, although several other cell type speci®c heterodimers have been identi®ed . Upon exposure of cells to growth factors and cytokines such as epidermal growth factor (EGF), interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFa), a series of signaling events target IkB for degradation, promoting nuclear translocation of NF-kB. NF-kB binds to DNA at its response elements and activate the expression of genes involved in in¯ammation, cell cycle, invasion, metastasis, angiogenesis and antiapoptosis (Barkett and Gilmore, 1999; Ghosh et al., 1998) .
Several laboratories including ours have demonstrated constitutive activation of NF-kB in a variety of cancers (Bargou et al., 1997; Cogswell et al., 2000; Dong et al., 1999; Nakshatri et al., 1997; Reuther et al., 1998; Shattuck-Brandt and Richmond, 1997; Sovak et al., 1997) . We have shown that NF-kB is constitutively active in breast cancer cells, which correlated with increased expression of pro-metastatic and anti-apoptotic genes (Nakshatri et al., 1997; Newton et al., 1999; Patel et al., 2000) . In addition, we and others have shown that cancer cell-derived IL1a and/or overexpression of epidermal growth factor receptor (EGFR) play a role in constitutive NF-kB activation in breast cancer (Biswas et al., 2000; Nozaki et al., 2000) . However, it is not clear whether any other oncogene/growth factor signaling pathways that are ampli®ed in breast cancer play a role in constitutive NF-kB activation. For example, c-Myc is ampli®ed or overexpressed in breast cancer (Escot et al., 1986) . Similarly, her2/neu, which belongs to epidermal growth factor receptor superfamily, is ampli®ed in 30% of breast cancer (Harari and Yarden, 2000) . The ras-signaling pathway is altered in breast cancer (Clark and Der, 1995) . Heregulin, which serves as a ligand for speci®c dimers of epidermal growth factor superfamily receptors, plays a role in invasive and hormoneindependent growth of breast cancer (Lupu et al., 1996) .
To further understand the signaling cascades involved in NF-kB activation in breast cancer, we studied NF-kB activation in cancer cell lines derived from transgenic mice that overexpress speci®c oncogene/growth factors in the mammary gland (Amundadottir and Leder, 1998). The cell lines were derived Figure 1 Constitutive and inducible NF-kB DNA binding activity in transgenic cell lines. Whole cell extracts (lanes 1 ± 16 and 21 ± 24) or nuclear extracts (lanes 17 ± 20) from indicated cell lines were subjected to EMSA with NF-kB, AP-1 or SP-1 probe. Whole cell extracts were prepared from cells either untreated or treated for 1 h with TNFa (4 ng/ml), IL-1a (5 ng/ml) or TPA (125 nM). In supershift assays (lanes 21 ± 24), DNA : protein complex was incubated with appropriate antibodies for 10 min before starting electrophoresis from c-Myc, heregulin, her2/neu and v-Ha-ras transgenic mice and some of the signaling events in these cell lines have been characterized previously (Amundadottir and Leder, 1998) . The c-Myc, neu and v-Ha-ras cell lines but not the heregulin cell line display higher level of ERK/MAPK activity and are growth inhibited by ERK inhibitor PD098059. PKC inhibitors prevent anchorage independent growth of c-Myc, neu and vHa-ras but not heregulin cell line. PI3 kinase activity is highest in heregulin and neu cell lines compared to other cell lines and the PI3 kinase inhibitor LY294002 inhibits anchorage independent growth of all four cell types. There is no oncogene speci®city with respect to Jun-N-terminal kinase (JNK) activity (Amundadottir and Leder, 1998) .
In this report, we show constitutive NF-kB activation in the heregulin transgenic cell line. Heregulindependent NF-kB activation correlated with phosphorylation of ErbB3 and EGFR. NF-kB DNA binding activity in these cells can be reduced by LY294002, the protein kinase A (PKA) inhibitor H-89 and the IkB kinase inhibitor parthenolide but not PD098059 and PKC inhibitor H-7. Although neu overexpression did not result in constitutive NF-kB activation, neu potentiated TNFa-induced NF-kB activity. Similarly, c-Myc potentiated TPA-induced NF-kB DNA binding activity. These results suggest that speci®c oncogene/ growth factor pathways are involved in constitutive and inducible NF-kB activation in breast cancer.
Results
Constitutive NF-kB DNA binding activity in heregulin transgenic cell line
To measure constitutive NF-kB binding activity, whole cell extracts from various cell lines were subjected to electrophoretic mobility shift assays (EMSAs) using NF-kB as a probe (Figure 1 ). NF-kB DNA binding activity in cells treated for 1 h with TNFa, IL-1a or TPA was also measured simultaneously. DNA binding of the general transcription factor SP-1 was determined to ensure the integrity of extracts. NF-kB DNA binding activity among untreated cells was restricted only to heregulin cells (Figure 1 , lanes 1, 5, 9 and 13). When nuclear extracts instead of whole cell extracts were used in the assay, highest DNA binding activity was seen with heregulin cells followed by c-Myc cells (lanes 17 ± 20). The NF-kB : DNA complex in heregulin cells contains the p65 subunit as determined by antibody supershift assay (lanes 21 ± 24). Inducible NF-kB DNA binding activity was observed in all cell types. In contrast to variable constitutive and inducible NF-kB DNA binding activity, AP-1 DNA binding activity, which is also targeted by oncogenes and growth factors in cancer cells, appears to be modulated by c-Myc (Figure 1, lanes 1 ± 4) . How c-Myc speci®cally upregulates AP-1 DNA binding activity remains to be investigated. Ideally, it is appropriate to compare NF-kB and AP-1 DNA binding activity in transgenic cell lines with normal mammary epithelial cells. However, such experiments are not possible because normal mammary epithelial cells can be cultured only in growth factor-rich media; some of which can induce NF-kB. Moreover, normal or immortalized mammary epithelial cells grown in regular cell culture media show elevated NF-kB due to stress (data not shown). Because constitutive NF-kB activation was not observed in all transgenic cell lines, we conclude that speci®c oncogenes/growth factors in¯uence the DNA binding of NF-kB and AP-1 in cancer cells.
Her2/neu potentiates TNFa-induced NF-kB activation
We observed considerable variation in the level of inducible NF-kB DNA binding activity among various (Figure 1 , lanes 1 ± 16). To determine whether speci®c oncogenes play any role in kinetics of NF-kB activation, time course of induction was measured. Cells were treated with TNFa, TPA or IL-1a and extracts were prepared at various time points. Integrity of proteins was veri®ed by measuring DNA binding of SP-1. Fold induction of NF-kB DNA binding activity was calculated by densitometric scanning and NF-kB DNA binding in untreated cells for each cell type was set arbitrarily as one unit. TNFa, TPA and IL-1a had only modest eect on NF-kB DNA binding activity in heregulin cells (Figure 2 ). In contrast, TNFa rapidly induced NF-kB DNA binding in neu cells, which peaked within 15 min (21-fold) and persisted even after 2 h (14-fold, lanes 1 ± 5). Although TNFa induced NFkB DNA binding activity in c-Myc and v-Ha-ras cells (seven-and 16-fold respectively), overall DNA activity was much lower than that in neu cells and only residual DNA binding (twofold) was observed after 2 h of induction. TPA-induced NF-kB DNA binding was more pronounced (15-fold) in c-Myc cells compared to other cell types (nine-and eightfold in neu and v-Haras cells, respectively, lanes 6 ± 9). IL-1a induced NFkB DNA binding was higher in c-Myc cells compared to other cell types (Figure 2 , lanes 10 ± 14). These results suggest that oncogene/growth factor initiated signaling cascades in¯uence not only constitutive binding but also kinetics of TNFa (TPA to a lesser extent) induced NF-kB DNA binding activity. Whether these oncogenes/growth factor-initiated signaling pathways determine the duration of NF-kB activation by in¯uencing acetylation status of NF-kB remains to be determined .
NF-kB subunits expression and transcriptional activity in various cell types
Constitutive NF-kB DNA binding activity in heregulin cells could be due to overexpression of NF-kB subunits or enhanced turnover of IkB proteins. To address this issue, we measured the expression level of p65, p50, IkBa and IkBb (Figure 3a ). p65 and p105 (the precursor for p50) were expressed at a similar level in all four cell types. When IkB level were normalized for aTubulin level, a signi®cant cell type speci®c dierence was observed with IkBb. IkBb level was highest in cMyc cells and least in heregulin cells. Lower level of IkBb in heregulin cells is most likely due to reduced Cell extracts were subjected to immunoprecipitation followed by Western blotting with indicated antibodies. EGFR : neu heterodimers appear to be more common than neu : ErbB3 heterodimers and heregulin had no eect on heterodimerization (c) Heregulin induces phosphorylation of EGFR, neu and ErbB3. Extracts from untreated cells or cells treated with heregulin for 10 min were subjected to immunoprecipitation followed by Western blotting with indicated antibodies. Note that heregulin induced phosphorylation of all three receptors and promotes interaction of receptors with p85 subunit of PI3 kinase. Also, it enhanced EGFR : ErbB3 and neu : ErbB3 heterodimerization transcription of IkBb but not due to enhanced turnover of this protein, as determined by reverse transcriptase-polymerase chain reaction and protein stability measurements (data not shown). Whether speci®c oncogene/growth factors regulate NF-kB activity by altering the expression of IkBb remains to be investigated. IkBa was lower in c-Myc and neu cells compared to other cells, which may have greater in¯uence on inducible but not constitutive NF-kB activation in these cells.
To investigate whether enhanced NF-kB DNA binding in heregulin cells correlates with increased transcriptional activity, transient transfection assay with NF-kB-dependent reporter (NF-kB/CAT) and a similar reporter with mutated NF-kB binding sites was performed (Figure 3b ). Reporter with mutated NF-kB binding sites did not show any activity in all cell types tested (data not shown). In contrast, constitutive NFkB/CAT reporter activity (10 ± 15-fold higher than mutant reporter) was observed in heregulin cells, which correlated with the level of DNA binding observed in these cells. A modest constitutive activity of the NFkB/CAT reporter was observed in neu cells but not in c-Myc cells. There was a discrepancy with respect to inducible DNA binding activity and transcriptional activation. For example, although TNFa induced NFkB DNA binding in neu cells is comparable or higher than in heregulin cells (Figure 1 ), corresponding increase in transcriptional activity was not observed in neu cells. Similar discrepancy was also noted in TPA treated cells. Therefore, DNA binding alone does not re¯ect transcriptional activity of NF-kB, which is consistent with our previous report in human breast cancer cell lines (Newton et al., 1999) . It should be noted that transactivation but not DNA binding of p65 subunit of NF-kB is regulated by phosphorylation, which may dier among transgenic cell lines (Madrid et al., 2001; Sizemore et al., 1999) . In addition, a recent study also indicated that IKKa modulates NF-kBmediated gene expression without signi®cantly aecting DNA binding activity (Senftleben et al., 2001) .
Exogenous heregulin induces NF-kB in v-Ha-ras but not c-Myc cells
Constitutive NF-kB activation in heregulin cells could be due to autocrine activity of heregulin or due to mechanisms independent of heregulin expression. Lack Figure 6 Tryphostin AG1517 but not emodin blocks NF-kB activation by heregulin. (a) The eect of Tryphostin AG1517 (Trp-AG) and emodin on heregulin induced NF-kB activity in MCF-7 cells. Cells were pre-incubated with Tryphostin AG1517 (10 mM) or emodin (40 mM) for 1 h followed by incubation with heregulin for 15 min. Cell extracts were subjected to EMSA with either NFkB or SP-1 probe. (b) Eect of Tryphostin AG1517 and emodin on receptor phosphorylation. Extracts from experiments in a were subjected to immunoprecipitation followed by Western blotting with indicated antibodies. Note that Tryphostin AG1517 inhibited heregulin induced phosphorylation of all three receptors whereas emodin only blocked phosphorylation of neu. NS=non-speci®c of neutralizing antibodies against heregulin expressed in the transgenic cell line prevented us from testing this possibility directly. Instead, we determined the eect of exogenous heregulin on NF-kB DNA binding of all four cell lines. Heregulin induced NF-kB in v-Ha-ras cells but not in c-Myc cells (Figure 4a ). NF-kB DNA binding activity was induced weakly by heregulin in neu cells. These results suggest that heregulin can directly induce NF-kB in a cell type speci®c manner.
Heregulin serves as a ligand for the ErbB3 homodimer and the ErbB3 : ErbB4 heterodimer and it can induce heterodimerization between neu and EGFR (Olayioye et al., 2000; Riese and Stern, 1998) . To determine whether cell type speci®city in heregulin mediated NF-kB activation is due to dierential expression of these receptors, Western blotting was performed (Figure 4b ). EGFR expression was least in the c-Myc cell line, which correlated with a lack of NFkB activation by heregulin in these cells. Neu expression was highest in neu cells and least in heregulin cells. ErbB3 antibody recognized a slower migrating and a faster migrating protein in v-Ha-ras , PKA inhibitor H-89 (10 mM), PKC inhibitor H-7 (60 mM) or IKK inhibitor parthenolide (5 mM) for 3 h. Subsequently cells were incubated with heregulin (50 ng/ml) for 15 min and cell extracts were subjected to EMSA with NFkB probe. IkBa level in these extracts was measured by Western blotting. (b) The eect of inhibitors on constitutive NF-kB activity in heregulin transgenic cells. Transgenic cells were incubated with indicated inhibitors for 3 h and cell extracts were analysed for NF-kB and SP-1 DNA binding activity as in a (top panel). In the bottom panel, the eect of inhibitors on the transcriptional activity of NF-kB is shown. Cells were transfected with NF-kB/CAT as in Figure 3 and treated with indicated inhibitors for 12 h. CAT activity in untreated cells was set as one unit cells. While c-Myc and heregulin cells expressed mostly the slower migrating species of ErbB3, neu cells expressed only the faster migrating ErbB3. None of these cells expressed ErbB4 (data not shown). Although ErbB family receptors are dierentially expressed, there was no dierence in the expression level of the p85 subunit of PI3 kinase, a downstream signaling molecule for ErbB receptors (Olayioye et al., 2000) .
To determine whether NF-kB activation by heregulin correlates with phosphorylation of ErbB receptors, we performed immunoprecipitation with receptor speci®c antibodies followed by Western blotting with phosphotyrosine antibodies or direct Western blotting with phosphospeci®c antibody. All three receptors were constitutively phosphorylated in heregulin and neu cells (Figure 4c ). In contrast, heregulin induced phosphorylation of EGFR and ErbB3 but not neu in v-Ha-ras cells. Although ErbB3 is phosphorylated in neu cells, its mobility was distinct from ErbB3 in heregulin and v-Ha-ras cells, which is consistent with the unique mobility pattern of this protein in these cells. However, we cannot rule out the possibility that phosphotyrosine antibody detected neu in neu : ErbB3 heterodimer rather than ErbB3 homodimer in these cells. None of the receptors were phosphorylated in c-Myc cells. Taken together, it appears that phosphorylation of neu is not required for NF-kB activation. These results also show a correlation of ErbB3 and EGFR phosphorylation with heregulin mediated NF-kB activation.
Heregulin-induced changes in heterodimerization among ErbB members were measured by immunoprecipitation/Western blotting. EGFR : neu heterodimer was predominant over neu : ErbB3 heterodimer ( Figure  4 ) and heterodimerization was not in¯uenced by heregulin. EGFR : ErbB3 heterodimers were not detected in these cells (data not shown). These results suggest that heregulin induces selective phosphorylation of EGFR and ErbB3 without altering their heterodimerization status in transgenic cell lines.
Heregulin induces NF-kB in MCF-7 breast cancer cells
To further elucidate the mechanism of NF-kB activation by heregulin, a time course of NF-kB activation was measured in human breast cancer cell line MCF-7. These cells lack constitutively active NFkB and express all four ErbB receptors in the order of ErbB34neu4EGFR4ErbB4 (Aguilar et al., 1999; Nakshatri et al., 1997) . Heregulin-mediated induction of NF-kB was observed within 30 min and peaked at 1 h (Figure 5a ). NF-kB activation was observed within 15 min in some experiments, depending on the aliquot of commercial heregulin (data not shown, see also Figures 6 and 7) . NF-kB activation correlated with phosphorylation and modest degradation of IkBa but not IkBb (Figure 5b, lanes 1 ± 7) . In contrast to heregulin, TNFa induced rapid phosphorylation and almost complete degradation of IkBa in these cells (Figure 5b, lanes 8 ± 16) . Furthermore, NF-kB DNA binding was observed within 10 min of TNFa addition and overall DNA binding was four times greater than in heregulin treated cells. The quantitative and qualitative dierences in TNFa and heregulin mediated NF-kB could be to dierences in their ability to activate IKK complex.
Immunoprecipitation/Western blotting was performed to determine heregulin-mediated changes in phosphorylation and heterodimerization among ErbB members. Immunoprecipitation with EGFR, neu and ErbB3 antibody followed by Western blotting with phosphotyrosine antibody revealed phosphorylation of all three receptors after addition of heregulin to MCF-7 cells (Figure 5c ). Heregulin enhanced the coprecipitation of ErbB3 with EGFR and Neu. Curiously the amount of EGFR immunoprecipitated by EGFR antibody was reproducibly higher in heregulin treated cells compared to untreated cells (compare lanes 1 and 2, WB : EGFR). Phosphorylation and/or co-precipitation of these receptors correlated with heregulindependent recruitment of p85 subunit of PI3 kinase to receptors (Figure 5c ). Taken together, these results suggest that heregulin-induced phosphorylation and/or heterodimerization of ErbB receptors promotes the recruitment of downstream signaling molecules such as p85 to receptors. The receptor : downstream signaling molecule complex may activate kinases, such as IKK, that phosphorylate IkBa and induce NF-kB.
Neu phosphorylation is not required for NF-kB activation by heregulin
To determine whether phosphorylation of ErbB receptors is essential for NF-kB activation by heregulin, we measured NF-kB activation in cells pretreated with Tryphostin AG1517 or emodin. Tryphostin AG1517 blocks phosphorylation of all three receptors whereas emodin is a more speci®c inhibitor of neu (Zhang et al., 1995) . Tryphostin AG1517 but not emodin reduced NF-kB activation by heregulin in MCF-7 cells (Figure 6a ). Note than in emodin treated cells neu was not phosphorylated upon stimulation with heregulin and emodin did not prevent recruitment of p85 to ErbB3 (Figure 6b ). In contrast, Tryphostin AG1517 blocked phosphorylation of all three receptors by heregulin and prevented recruitment of p85 to ErbB3 (Figure 6b) . From these results, we conclude that NF-kB activation by heregulin correlates with EGFR and ErbB3 but not neu phosphorylation. These results are also consistent with our observations in transgenic cell lines where NF-kB activation in vHa-ras cells correlated with EGFR and ErbB3 but not neu phosphorylation (Figure 4 ).
PI3 kinase, PKA and IKK are required for NF-kB activation by heregulin
We used inhibitors of various kinases to delineate signaling events downstream of ErbB receptors in NFkB activation by heregulin. The PI3 kinase inhibitor LY294002, the PKA inhibitor H-89 and the IKK inhibitor parthenolide but not the ERK/MAPK inhibitor PD098059 or PKC inhibitor H-7 reduced heregulin-induced NF-kB DNA binding activity in MCF-7 cells (Figure 7a ) (Amundadottir and Leder, 1998; Hehner et al., 1999) . Similar results were obtained in the heregulin transgenic cell line ( Figure  7b, top panel) . Inhibition of NF-kB DNA binding by these inhibitors correlated with reduced NF-kB transcriptional activity in heregulin transgenic cell line (Figure 7b, bottom panel) . Although parthenolide almost completely inhibited NF-kB DNA binding, its ability to inhibit transactivation is modest because its biological activity lasts 55 h in culture (Nozaki et al., 2001 ). In addition, unlike PI3 kinase/AKT and PKA inhibitors, parthenolide is less likely to eect the transactivation potential of p65 subunit of NF-kB. Heregulin-induced IkBa degradation was observed in LY294002 or H-89 but not in parthenolide pretreated cells (Figure 7a ). These results suggest that PI3 kinase and PKA prevent NF-kB DNA binding activity independent of IkBa degradation.
Heregulin transgenic cells are resistant to TNFa
Previous reports have indicated that NF-kB confers resistance to TNFa (Wang et al., 1996) . To determine whether constitutive NF-kB activity in heregulin cells correlates with resistance to TNFa, we measured the eects of increasing concentration of TNFa on viability of all transgenic cell lines. The c-Myc cells were sensitive to TNFa, which is consistent with very low constitutive NF-kB DNA binding activity in these cells (Figure 8 ). This is not surprising given the previous report that c-Myc potentiates TNFa-induced apoptosis by inhibiting NF-kB activity (Klefstrom et al., 1997) . While the v-Ha-ras cells were moderately sensitive to TNFa, heregulin cells were resistant to TNFa. In contrast, neu cells were not only resistant to TNFa but were also growth stimulated at lower concentrations of TNFa. Thus, resistance of transgenic cell lines to TNFa-induced cell death correlates with constitutive or inducible NF-kB DNA binding activity. Although there are no reports indicating any role for NF-kB in TNFa stimulated growth, there is substantial evidence for the role of NF-kB in resistance to TNFa (Wang et al., 1996; Zhou et al., 2000) . Note that all cell types acquired resistance to TNFa after continuous passage in culture (data not shown).
Discussion
Several reports by ourselves and others have indicated constitutive NF-kB activation in breast cancer cells (Cogswell et al., 2000; Nakshatri et al., 1997; Sovak et al., 1997) . NF-kB is also activated in non-apoptotic epithelial cells of involuting mammary gland (Clarkson et al., 2000) . NF-kB activation is essential at the early step in carcinogen-driven transformation of mammary epithelial cells (Kim et al., 2000) . Constitutive NF-kB activation correlates with increased activity of IKK kinase and casein kinase II in primary breast cancers (Romieu-Mourez et al., 2001) . However, the signaling pathways responsible for increased IKK/NF-kB activity is not known. We have investigated whether speci®c oncogene/growth factors play a role in constitutive and inducible activation of NF-kB in breast cancer cells.
Heregulin mediates constitutive NF-kB activation in breast cancer cells
Our study suggests NF-kB is one of the downstream targets of heregulin in breast cancer cells. NF-kB activation by heregulin involved phosphorylation and degradation of IkBa. However, kinetics as well as intensity of NF-kB activation is dierent from that of TNFa. It should be noted that although both TNFa and heregulin induce NF-kB in MCF-7 cells, only TNFa induces parallel apoptotic pathway in these cells. Therefore, unlike in TNFa-treated cells, the role of NF-kB in heregulin-treated cells is on growth and invasion rather than on survival. In fact, expression of some of the genes induced by heregulin including urokinase plasminogen activator, urokinase plasminogen activator receptor, vascular endothelial growth factor, IEX1, DAD-1 and Bcl-X L is dependent on NFkB (Patel et al., 2000; Ravi et al., 2001; RomieuMourez et al., 2001; Sweeney et al., 2001; Yen et al., 2000) . Heregulin mediated induction of NF-kB involves activation of IKK because IKK inhibitor parthenolide (Hehner et al., 1999) prevented NF-kB activation (Figure 7) . The PI3 kinase inhibitor LY294002 and the PKA inhibitor H-89 also reduced NF-kB activation. However, these inhibitors failed to inhibit IkBa degradation by heregulin, which suggests that PI3 kinase and PKA are involved in NF-kB activation subsequent to IkBa degradation. This observation is consistent with the recent ®nding by others that, depending on cell type, PI3 kinase regulates NF-kB activation by either inducing IkBa degradation or in¯uencing a step subsequent to IkBa degradation (Koul et al., 2001; Ozes et al., 1999) . It is possible that these kinases may enhance the interaction of NF-kB with DNA as demonstrated previously with PKA (Zhong et al., 1998) . Alternatively, PI3 kinase and PKA are involved in non-classical or the second evolutionarily conserved pathway involved in NF-kB activation (Senftleben et al., 2001) . Although inhibitors of PI3 kinase and PKA reduced heregulin-mediated NF-kB activation, activities of these kinases alone are not sucient for NF-kB activation by heregulin. This is based on the observation that all transgenic cell lines contained similar level of PI3 kinase activity (as measured by AKT phosphorylation) and PKA activity was highest in v-Ha-ras cells followed by neu, c-Myc and heregulin cells (data not shown).
Heregulin mediated NF-kB activation correlates with EGFR and ErbB3 but not neu phosphorylation
Heregulin binds to ErbB3 and ErbB4 homodimers, ErbB3 : neu and ErbB3 : ErbB4 heterodimers and acti-vates a number of signaling events (Olayioye et al., 2000) . Recently it was also shown that heregulin induces heterodimerization of neu with EGFR (Riese and Stern, 1998) . Binding of heregulin to these receptors leads to receptor phosphorylation. In most cases phosphorylation of the receptor is through kinase activity of the receptor itself with the exception of ErbB3, which lacks kinase activity (Olayioye et al., 2000) . We have used a number of approaches to determine whether phosphorylation status of these receptors correlates with NF-kB activation. Although addition of heregulin to MCF-7 cells leads to phosphorylation of all three receptors ( Figure 5 ), heregulin induced NF-kB in v-Ha-ras cells without inducing neu phosphorylation (Figure 4) . These results suggest that activation of neu is not essential for NF-kB activation by heregulin. Consistent with this possibility, emodin, which blocked neu phosphorylation by heregulin, had no eect on NF-kB activation ( Figure  6 ). Because all of the transgenic cell lines used lack ErbB4, this receptor is less likely to be involved in NFkB activation (data not shown). In contrast, NF-kB activation correlated with EGFR and ErbB3 phosphorylation. Tryphostin AG1517, which blocks EGFR and ErbB3 phosphorylation, reduced NF-kB activation ( Figure 6 ). Furthermore, heregulin-mediated NF-kB activation in v-Ha-ras cells correlated with EGFR and ErbB3 phosphorylation (Figure 4c ). Additional studies involving overexpression of individual or combination of receptors in cells that lack these receptors is essential for de®ning the role of individual ErbB receptors in heregulin mediated activation of NF-kB.
Heregulin mediated NF-kB activation is cell type specific
We observed that exogenous heregulin did not induce NF-kB in all transgenic cell lines. For example, heregulin failed to induce NF-kB in the c-Myc cell line, and induction was very weak in the neu cell line. Lack or reduced NF-kB activation in these two cells correlated with either lower EGFR level or unique ErbB3 species, which may be a splice variant ( Figure  4b ). It should be noted that several isoforms of ErbB3 with distinct biological activity have been reported (Lee and Maihle, 1998) . It is tempting to speculate that NFkB activation by heregulin depends on expression status of EGFR and ErbB3 isoforms. Because ErbB3 lacks autophosphorylation activity and our results have shown that heregulin induces ErbB3 phosphorylation in the absence of neu activation (Figure 6 ), additional kinases activated by heregulin may involved in phosphorylation of ErbB3. It is also known that even in the absence of ErbB kinase activity, phosphorylation of speci®c residues in the cytoplasmic tail of the ErbB receptors by non-receptor kinase such as Src and Jak can provide a docking site for cytoplasmic signaling (Kroiher et al., 2001) . The expression status of these non-receptor kinases may determine cell type-speci®c activation of NF-kB by heregulin. Additionally, it has been demonstrated recently that ErbB3 recruits the adapter protein Grb7 in heregulin-dependent manner (Fiddes et al., 1998) . However, the biological signi®-cance of this association is not known. Assuming that Grb7 is required for heregulin-mediated NF-kB activation, the expression status of this adapter protein may have a role in cell type-speci®c NF-kB activation by heregulin.
Sequential signaling events starting from heregulinmediated EGFR and ErbB3 phosphorylation to NFkB activation at present is purely a speculation and beyond the scope of this investigation. EGFR has been shown to activate NF-kB by forming a complex with receptor interacting protein (RIP) and NF-kB inducing kinase (NIK) (Habib et al., 2001) . It is possible that heregulin promotes the formation of a similar complex, which then activates NF-kB. ErbB3 in contrast may enhance NF-kB activation by stimulating PI3 kinase activity. Our proposed model for NF-kB activation by heregulin involves the following steps: (1) Heregulin activates EGFR, which engages RIP and NIK; (2) Non-receptor tyrosine kinases activated by heregulin phosphorylate ErbB3 leading to PI3 kinase activation; (3) PI3 kinase along with EGFR : RIP : NIK complex then activates NF-kB. If this model is veri®ed, it would provide a rationale to develop inhibitors that speci®-cally block NF-kB activation by heregulin.
Materials and methods

Breast cancer cell lines
The c-Myc expressing cell line 16MB9A, the heregulin overexpressing cell line IJ9921, the neu overexpressing cell line SMF and the v-Ha-ras overexpressing cell line SH1.1 have been described previously (Amundadottir and Leder, 1998) and are maintained in DMEM+10% FCS. MCF-7 cells were maintained in MEM+10% FCS.
Electrophoretic mobility shift assays (EMSAs)
EMSA with whole cell extracts was performed as described previously (Patel et al., 2000) . Brie¯y, cell pellets were resuspended in whole cell extract buer (20 mM HEPES pH 7.5, 400 mM KCl, 0.5 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 20% glycerol, 1% NP40, 100 mM sodium orthovanadate, 1 mM sodium¯uoride, 1 mM b-glycerophosphate, 0.5 mM PMSF, 2 mg/ml of aprotenin, pepstatin A and leupeptin). Cell lysates were prepared by three cycles of freezing-thawing in liquid nitrogen and ice. Nuclear extracts were prepared as described previously (Dignam et al., 1983) . EMSA reactions were performed with 6 mg of protein in a buer containing 10 mM Tris pH 7.5, 1 mM EDTA, 1 mM DTT, 100 mM KCl (®nal concentration after adjusting for KCl in the cell lysate), 10% glycerol and 2 mg poly dI : dC. For antibody supershift assays, DNA : protein complex was incubated with antibodies for 10 min before loading to gels. TNFa, IL-1a and heregulin were purchased from R&D systems (Minneapolis, MN, USA) whereas TPA was from Sigma Chemicals (St. Louis, MO, USA). All EMSAs were repeated 2 ± 4 times with similar results.
Immunoprecipitation and Western blotting
Cell extracts for immunoprecipitation and Western blotting were prepared in radioimmunoassay buer (50 mM Tris pH 7.5, 0.25% sodium deoxycholate, 1% NP 40, 150 mM NaCl, 1 mM EDTA, 100 mM sodium orthovanadate, 1 mM sodium¯uoride, 1 mM b-glycerophosphate, 0.5 mM PMSF, 2 mg/ml aprotenin, leupeptin and pepstatin). One hundred micrograms of protein was immunoprecipitated with antibodies, run on an SDS ± PAGE and subjected to immunoblotting. Western blotting was performed with 50 mg of extract. Antibody against phosphoEGFR (Tyr845) was purchased from Cell Signaling (Beverly, MA, USA) whereas p65 antibody was from Upstate Biotechnology (Lake Placid, NY, USA). Remaining antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Both Western blotting and immunoprecipitation were repeated 2 ± 4 times with similar results.
Transient transfection assays
NF-kB/CAT reporter gene and the CAT reporter with mutated NF-kB sites are described previously (Nakshatri et al., 1997) . Cells were transfected with 5 mg of CAT reporter along with rouse sarcoma virus enhancer-promoter-driven bgalactosidase gene to monitor transfection eciency. TNFa (4 ng/ml), IL-1a (5 ng/ml) or TPA (125 nM) was added 24 h after transfection and cells were harvested 36 h after transfection. CAT activity in equal number of b-galactosidase units was measured as described previously (Nakshatri et al., 1997) .
TNFa sensitivity
One 610 4 cells were plated in 96 well plates and appropriate amount of TNFa was added 24 h after plating. Cell survival was measured 48 h after TNFa addition by MTT assay as described previously (Patel et al., 2000) .
Abbreviations NF-kB, Nuclear factor-kappaB; IkB, Inhibitor of kappaB; TNF, Tumor necrosis factor; IL-1, Interleukin 1; TPA, 12-O-tetradecanoylphorbol-13-acetate; EGFR, Epidermal growth factor receptor; PKA, Protein kinase A; EMSA, Electrophoretic mobility shift assay.
